English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16984/19280 (88%)
Visitors : 8632714      Online Users : 462
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27601


    標題: Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus
    作者: Wang, Jiun-Ling
    Tang, Hung-Jen
    Hsieh, Pang-Hsin
    Chiu, Fang-Yao
    Chen, Yen-Hsu
    Chang, Ming-Chau
    Huang, Ching-Tai
    Liu, Chang-Pan
    Lau, Yeu-Jun
    Hwang, Kao-Pin
    Ko, Wen-Chien
    Wang, Chen-Ti
    Liu, Cheng-Yi
    Liu, Chien-Lin
    Hsueh, Po-Ren
    貢獻者: 醫藥化學系
    關鍵字: Fusidic Acid
    Meticillin-Resistant Staphylococcus Aureus (Mrsa)
    Bone And Joint Infection
    Rifampicin
    Combination Therapy
    日期: 2012-08
    上傳時間: 2014-03-21 16:14:52 (UTC+8)
    出版者: Elsevier Science Bv
    摘要: There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e. g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs. (C) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
    Appears in Collections:[醫藥化學系 ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML393View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback